Clinical Trial Update: A Two-year Study of Telbivudine in HBeAg Negative Hepatitis [Phase 4]

View source ↗

Summary

Phase 4 study evaluating telbivudine over two years in patients with chronic hepatitis B who are HBeAg-negative has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Telbivudine (telbivudine)

Snippet

Sponsor: Third Affiliated Hospital, Sun Yat-Sen University | Conditions: Hepatitis B, Chronic | Phase 4 | Status: COMPLETED